<DOC>
	<DOCNO>NCT00890968</DOCNO>
	<brief_summary>The purpose study determine whether Triamcinolone Acetonide ( TAC ) DuraPeel safe effective treatment hand dermatitis .</brief_summary>
	<brief_title>Safety Efficacy Study Triamcinolone Acetonide DuraPeel Treat Hand Dermatitis</brief_title>
	<detailed_description>Triamcinolone acetonide commonly use , safe , effective topical corticosteroid indicate relief inflammatory pruritic manifestation corticosteroid-responsive dermatosis . However , effectiveness topical agent creams ointment limit patient ' routine activity use bare hand may remove topical agent hand . The use topical corticosteroid vehicle allow product remain contact skin susceptible inadvertent removal would beneficial . The DuraPeel membrane expect optimize exposure steroid remain treatment area prolong period time . This study design evaluate efficacy safety Triamcinolone Acetonide 0.5 % DuraPeel . Eligible subject receive Triamcinolone Acetonide 0.5 % DuraPeel Placebo DuraPeel . The study duration approximately 4 week .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Hand Dermatoses</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Clinical diagnosis stable chronic hand dermatitis ( great 6 week duration ) KOHnegative Dermatitis mild moderate severity , define Investigator 's Global Assessment ( score 2 3 Target Hand ) Individual sign hand dermatitis disease least mild scale mild erythema ( score 2 Target Hand ) Written informed consent Subject female pregnant , lactate , plan become pregnant study Spontaneously improve rapidly deteriorate hand dermatitis time enrollment ; subject may history wax wan disease past History hand dermatitis show unresponsive super potent ( Group 1 ) topical steroid Concurrent flare inflammatory skin disease ( e.g. , atopic dermatitis psoriasis ) anywhere body outside study area Bullous disorder hand , foot , mouth disease ( HFMD ) ; however , subject dyshidrotic hand dermatitis pompholyx allow participate provide meet Inclusion/Exclusion criterion Known allergic mediate hand dermatitis ( e.g. , allergic latex , etc . ) Concurrent skin disease study area require concomitant topical treatment ( e.g. , tinea manuum , scabies , infect eczema , paronychia ) could interfere evaluation his/her dermatitis Pustular disease hand ( e.g. , acrodermatitis perstans continua ) . Used phototherapy , photochemotherapy , systemic immunomodulatory therapy ( systemic corticosteroid , methotrexate , retinoids cyclosporine ) , therapy within 30 day prior first application study medication know suspect , opinion investigator , effect hand dermatitis Prolonged exposure natural artificial source ( e.g. , UVB , UVA , etc . ) ultraviolet radiation within 30 day prior first application study medication intend exposure study Received intralesional therapy hand ( e.g. , corticosteroid ) within 30 day prior first application study medication Treated Grenz ray soft xray therapy hand within 6 month first application study medication Treated topical hand therapy ( e.g. , tar , topical corticosteroid , topical retinoids , topical antimicrobial , topical calcineurin inhibitor , Burrow 's solution soak ) within 7 day prior first application study medication know suspected effect hand dermatitis Received systemic antibiotic infection hand within 7 day prior first application study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>hand dermatitis</keyword>
	<keyword>hand eczema</keyword>
	<keyword>triamcinolone acetonide</keyword>
</DOC>